214 related articles for article (PubMed ID: 14974399)
1. Patent infringement. Court denies motion to alter patent claim decision.
AIDS Policy Law; 2003 Dec; 18(22):6. PubMed ID: 14974399
[No Abstract] [Full Text] [Related]
2. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
[No Abstract] [Full Text] [Related]
3. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
4. Use patents, carve-outs, and incentives--a new battle in the drug-patent wars.
Rai A
N Engl J Med; 2012 Aug; 367(6):491-3. PubMed ID: 22873529
[No Abstract] [Full Text] [Related]
5. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
6. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
7. A promise to a court doesn't avoid infringement.
Harrison C
Nat Rev Drug Discov; 2013 Nov; 12(11):820. PubMed ID: 24172324
[No Abstract] [Full Text] [Related]
8. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
9. FDA: approval of generic drug reversed by U.S. Court of Appeals.
Beliveau S
J Law Med Ethics; 2002; 30(1):120-2. PubMed ID: 11905262
[No Abstract] [Full Text] [Related]
10. Patent. Battle lines are drawn over generic AIDS drug.
AIDS Policy Law; 2005 Aug; 20(16):6. PubMed ID: 16161208
[No Abstract] [Full Text] [Related]
11. Judicial developments in the US Hatch-Waxman infringement safe harbor.
Swirnoff AH; Becker DM
Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
[TBL] [Abstract][Full Text] [Related]
12. Patent law rulings work in favor of generics.
Sipkoff M
Manag Care; 2007 Sep; 16(9):12, 14. PubMed ID: 17969743
[No Abstract] [Full Text] [Related]
13. Patent watch: US Supreme Court revises patent claim construction standards.
Noonan K
Nat Rev Drug Discov; 2015 Mar; 14(3):157. PubMed ID: 25722233
[No Abstract] [Full Text] [Related]
14. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
Panattoni LE
J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
[TBL] [Abstract][Full Text] [Related]
15. Patent watch: post-approval testing shielded from patent infringement.
Harrison C
Nat Rev Drug Discov; 2012 Sep; 11(9):666. PubMed ID: 23097768
[No Abstract] [Full Text] [Related]
16. The use of Food and Drug Administration 510(k) notifications in patent litigation.
Tolomeo DE
Food Drug Law J; 2004; 59(4):465-77. PubMed ID: 15875346
[TBL] [Abstract][Full Text] [Related]
17. FDA's role in administering the Hatch-Waxman Act.
Malkin BJ
Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
[No Abstract] [Full Text] [Related]
18. Epo, by any other name.
Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170
[No Abstract] [Full Text] [Related]
19. The Hatch-Waxman Act during patent prosecution and beyond.
Mahn TG
Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578
[No Abstract] [Full Text] [Related]
20. FDA's role in making exclusivity determinations.
Dickinson EH
Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
